ReBio Pharma Names Kristof Kunzmann, MBA, as Chief Financial Officer

Turku, Finland – ReBio Pharma has announced the appointment of Kristof Kunzmann, MBA, as Chief Financial Officer (CFO).

Kunzmann is a seasoned healthcare executive who comes to ReBio Pharma with more than 12 years of experience as CFO and COO of multi-site clinics and specialized lab businesses. He has a strong record in early-stage and private equity-backed environments.

“Kristof’s focus and expertise in scaling high-growth companies and building teams is an asset to ReBio as we continue to accelerate our research and operational activities,” says Vinod Vijayakumar, DPhil, CEO of ReBio Pharma. “His background in corporate finance and extensive experience working closely with investors brings essential capabilities to the company as we raise funding for future growth.”

Kunzmann has held roles as a healthcare-sector executive and advisor for diagnostics labs, cosmetic medicine, dentistry, dermatology, and residential care. He spent 10 years as an M&A advisor for UK, European, and US markets. Kunzmann earned an MBA from USC Marshall School of Business.

About ReBio Pharma

ReBio Pharma is a pre-clinical stage biotechnology company that has developed SiSu®, a novel, proprietary formulation technology that solves the safety and efficacy challenges other sustained release approaches have been unable to resolve. SiSu® is designed to steadily release effective levels of therapeutics within the eye while safely dissolving once drug release is completed, and can be tuned to the drug, indication, and duration of release required. ReBio Pharma is leveraging Sisu® to create a new franchise to transform the standard of care in the treatment of vision-threatening chronic eye diseases. Discover more at www.rebiopharma.com.